http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 14 May 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html <p align="center"><em>Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion</em><br/><em>Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform</em></p> <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or the “<strong>Company”</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q1+2026+Financial+Statements/26489936.html Thu, 14 May 2026 07:30:00 -0400 0NN A.01718595 A.26881573 AVCN AVCNF O.00786770 O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html <p align="justify">TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“<strong>Avicanna</strong>” or “<strong>Company</strong>) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“<strong>Circular</strong>”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“<strong>Meeting</strong>”).</p> <p align="justify">Detailed results of the vote for the election of directors held at the Meeting are set out below:</p> <table style="border-top: solid http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Results+of+Annual+General+and+Special+Meeting/26457687.html Fri, 08 May 2026 07:30:00 -0400 0NN A.26881573 AVCN AVCNF O.05097238 O.37304256